Daniel Haders

Dr. Daniel Haders II is the Co-Founder & CEO of Model Medicines, a leading generative AI biotech platform. He was recently named one of “The Top 50 Healthcare AI Entrepreneurs of 2025” and was featured by Bloomberg Intelligence in their “Vanguards of Healthcare” series.

Under Daniel’s leadership, Model Medicines has been widely recognized in the industry, having been named a Fierce Medtech “Fierce 15” company, one of GEN’s “Ten Companies to Watch in AI Drug Discovery,” and one of GreyB’s “5 Innovative AI Drug Development Startups to Watch in 2025.”

Prior to Model Medicines, Daniel launched a Digital Health Accelerator, where he built an early-stage investment portfolio of 25+ Digital Healthcare companies with investment results that would place the portfolio in the top decile. During his tenure, the accelerator was named one of the “Top Ten Global Digital Health Accelerators” & “The Best Accelerators & Incubators for FemTech Startups”.

As a scientist and pharmaceutical development leader at Lux Biosciences, Daniel helped develop LX214 from concept through a successful Phase I study. The formulation was later approved by the FDA under the name CEQUA in 2018.

Dr. Haders has served as a Board Member or Observer at multiple companies, including AppliedVR, Regenexx, and Consano Biologics. He is also a Faculty Member & Member of the Advisory Committee of the UCSD Digital Health Certificate Program & a Member of the BioMedX Oversight Committee at Columbia University Technology Ventures.

Dr. Haders holds a BS from Columbia University and a PhD in Biomedical Engineering from Rutgers University. He is a US Department of Education GAANN Fellow in Molecular, Cellular, and Nanosystems Engineering and a National Science Foundation IGERT Fellow in Integratively Engineered Biointerfaces. He holds a Certificate in Leadership and Strategy in Pharma and Biotech from the Harvard School of Business and has authored multiple patents and peer-reviewed manuscripts.